Nutshell Raises C1 Capital for Allosteric Drug Design

Company Nutshell Therapeutics / Shanghai Yudao Biotechnology Event Type Financing (C1 Round) Platform AlloStar — AI-Plus-Physics Allosteric and Conformational Drug Design Indication Oncology (p53 Y220C-Mutant Solid Tumors); NRF2-Driven Disease (Preclinical) Summary Nutshell Therapeutics, also known as Shanghai Yudao Biotechnology, announced a C1 financing of “tens…